ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · IEX Real-Time Price · USD
10.54
+0.09 (0.91%)
At close: Jul 19, 2024, 4:00 PM
11.00
+0.46 (4.36%)
Pre-market: Jul 22, 2024, 7:01 AM EDT
Company Description
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.
The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis.
It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Richard Lowenthal M.B.A., M.S., MSMSEL |
Contact Details
Address: 11682 El Camino Real, Suite 120 San Diego, California 92130 United States | |
| Phone | 858-771-9307 |
| Website | ars-pharma.com |
Stock Details
| Ticker Symbol | SPRY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671858 |
| ISIN Number | US82835W1080 |
| Employer ID | 81-1489190 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard Lowenthal M.B.A., M.S., MSMSEL | Founder, President, Chief Executive Officer and Director |
| Dr. Sarina Tanimoto M.B.A., M.D. | Co-Founder and Chief Medical Officer |
| Eric Karas | Chief Commercial Officer |
| Dr. Robert Bell Ph.D. | Co-Founder and Chief Science Officer |
| Kathleen D. Scott CPA | Chief Financial Officer |
| Brian T. Dorsey M.S. | Chief Operations Officer |
| Alexander A. Fitzpatrick Esq. | Chief Legal Officer and Secretary |
| Daniel Relovsky | Senior Vice President of Marketing |
| Harris Kaplan M.B.A. | Executive Vice President of Commercial Strategy |
| Justin Chakma | Chief Business Officer and Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2024 | 144 | Filing |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 28, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 17, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 11, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 11, 2024 | 144 | Filing |
| May 10, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |